Lubiprostone successfully completes Phase III efficacy trial in Japanese Patients suffering from Chronic Idiopathic Constipation.

Sucampo Pharmaceuticals Inc and Abbott announced that a pivotal Phase III clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data. The primary endpoint of this trial was a change in the number of spontaneous bowel movements (SBMs) at the end of the first week of treatment. This pivotal, double-blinded, placebo-controlled trial evaluated 124 Japanese CIC patients each of whom received one lubiprostone 24 micro g, or placebo, capsule twice daily for 28 days. As previously reported, Sucampo continues to …